Arcus Biosciences (RCUS) to Release Quarterly Earnings on Tuesday

Arcus Biosciences (NYSE:RCUS) is expected to be announcing its Q4 2025 results before the market opens on Tuesday, February 24th. Analysts expect the company to announce earnings of ($0.97) per share for the quarter. Investors are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Wednesday, February 25, 2026 at 4:30 PM ET.

Arcus Biosciences Stock Performance

NYSE RCUS opened at $18.87 on Tuesday. The company has a market capitalization of $2.04 billion, a PE ratio of -5.48 and a beta of 0.84. The company has a debt-to-equity ratio of 0.22, a quick ratio of 3.65 and a current ratio of 3.65. Arcus Biosciences has a 52-week low of $6.50 and a 52-week high of $26.40. The company has a 50-day simple moving average of $22.20 and a 200 day simple moving average of $17.92.

Insider Activity

In other news, General Counsel Carolyn C. Tang sold 7,658 shares of the company’s stock in a transaction on Tuesday, December 16th. The shares were sold at an average price of $21.88, for a total value of $167,557.04. Following the transaction, the general counsel owned 131,544 shares of the company’s stock, valued at approximately $2,878,182.72. This represents a 5.50% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, COO Jennifer Jarrett sold 11,225 shares of the stock in a transaction on Tuesday, December 16th. The stock was sold at an average price of $21.88, for a total value of $245,603.00. Following the completion of the sale, the chief operating officer owned 203,007 shares in the company, valued at $4,441,793.16. This trade represents a 5.24% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 265,887 shares of company stock worth $6,075,020 in the last three months. Insiders own 9.60% of the company’s stock.

Institutional Trading of Arcus Biosciences

A number of large investors have recently modified their holdings of the business. Strs Ohio purchased a new stake in Arcus Biosciences in the first quarter valued at approximately $67,000. Tower Research Capital LLC TRC raised its position in shares of Arcus Biosciences by 184.2% during the 2nd quarter. Tower Research Capital LLC TRC now owns 8,449 shares of the company’s stock valued at $69,000 after buying an additional 5,476 shares in the last quarter. Brevan Howard Capital Management LP purchased a new stake in shares of Arcus Biosciences during the 2nd quarter valued at $97,000. Corient Private Wealth LLC bought a new stake in shares of Arcus Biosciences during the 2nd quarter worth $180,000. Finally, iSAM Funds UK Ltd purchased a new position in Arcus Biosciences in the third quarter worth $190,000. Institutional investors own 92.89% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms recently commented on RCUS. Bank of America lifted their price target on shares of Arcus Biosciences from $17.00 to $26.00 and gave the stock a “neutral” rating in a report on Friday, November 28th. Wedbush set a $35.00 target price on Arcus Biosciences and gave the company an “outperform” rating in a research note on Wednesday, October 29th. Truist Financial set a $30.00 price target on Arcus Biosciences in a research report on Friday, December 12th. Wall Street Zen lowered Arcus Biosciences from a “hold” rating to a “sell” rating in a report on Saturday, February 7th. Finally, Morgan Stanley reaffirmed an “equal weight” rating and set a $20.00 price objective (down from $23.00) on shares of Arcus Biosciences in a report on Thursday, January 8th. Seven investment analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, Arcus Biosciences has a consensus rating of “Moderate Buy” and a consensus price target of $29.33.

Arcus Biosciences Company Profile

Arcus Biosciences is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel cancer immunotherapies. The company’s research platform centers on modulating tumor microenvironments and immune checkpoints through both small-molecule and antibody-based candidates. Arcus aims to enhance antitumor immune responses by targeting pathways such as the adenosine axis and inhibitory receptors on immune cells.

The company’s lead clinical programs include etrumadenant, an orally administered A2A adenosine receptor antagonist being evaluated in combination with anti-PD-1 therapy, and domvanalimab, an anti-TIGIT monoclonal antibody.